VYNE raises $88.2M, reports positive Phase 1b vitiligo data for VYN201

VYNE Therapeutics Inc.

$88.2M private placement closed Nov 1; cash runway extended through end of 2025.
Phase 1b: VYN201 mean F-VASI reduction 30.2% (1%) and 39.0% (2%) at 16 weeks; well-tolerated.
Phase 2b trial for VYN201 in vitiligo expected H1 2024; top-line results mid-2025.
VYN202 IND submission by year-end 2023; Phase 1a trial in Q1 2024; Phase 1b in psoriasis/RA H2 2024.
Q3 2023 GAAP net loss $6.6M, adjusted net loss $5.7M; cash runway through 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYNE Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2023.

Period: the three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116712

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.